Zymeworks (NASDAQ:ZYME) Price Target Raised to $47.00

Zymeworks (NASDAQ:ZYME) had its price objective upped by analysts at Stifel Nicolaus from $40.00 to $47.00 in a research note issued on Tuesday,Benzinga reports. The firm presently has a “buy” rating on the stock. Stifel Nicolaus’ target price would indicate a potential upside of 94.70% from the company’s previous close.

Other analysts also recently issued research reports about the company. B. Riley Financial reiterated a “buy” rating and set a $40.00 price target (up from $30.00) on shares of Zymeworks in a research note on Friday, November 21st. Citizens Jmp set a $32.00 target price on Zymeworks in a report on Wednesday, December 3rd. HC Wainwright increased their price target on Zymeworks from $26.00 to $32.00 and gave the company a “buy” rating in a report on Tuesday, November 18th. Weiss Ratings reissued a “sell (d-)” rating on shares of Zymeworks in a research report on Wednesday, January 21st. Finally, Zacks Research downgraded shares of Zymeworks from a “strong-buy” rating to a “hold” rating in a report on Wednesday, November 26th. Two research analysts have rated the stock with a Strong Buy rating, ten have given a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, Zymeworks currently has a consensus rating of “Moderate Buy” and an average price target of $35.70.

Zymeworks Trading Up 3.6%

NASDAQ ZYME traded up $0.83 during trading on Tuesday, reaching $24.14. 321,055 shares of the company’s stock were exchanged, compared to its average volume of 757,167. Zymeworks has a fifty-two week low of $9.03 and a fifty-two week high of $28.49. The company’s fifty day simple moving average is $23.90 and its 200-day simple moving average is $20.88. The firm has a market capitalization of $1.81 billion, a PE ratio of -28.74 and a beta of 1.23.

Zymeworks (NASDAQ:ZYME) last posted its quarterly earnings results on Wednesday, March 4th. The company reported ($0.55) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.35) by ($0.20). Zymeworks had a negative return on equity of 19.25% and a negative net margin of 47.16%.The company had revenue of $2.52 million during the quarter. During the same period last year, the business earned ($0.31) earnings per share. Zymeworks’s quarterly revenue was down 91.9% compared to the same quarter last year.

Insider Buying and Selling

In other Zymeworks news, CEO Kenneth Galbraith sold 30,424 shares of the stock in a transaction on Monday, January 12th. The stock was sold at an average price of $22.67, for a total transaction of $689,712.08. Following the completion of the transaction, the chief executive officer directly owned 226,842 shares in the company, valued at $5,142,508.14. This represents a 11.83% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, EVP Jeffrey T. L. Smith sold 9,310 shares of the business’s stock in a transaction dated Monday, January 12th. The shares were sold at an average price of $22.67, for a total transaction of $211,057.70. Following the completion of the transaction, the executive vice president owned 26,708 shares in the company, valued at approximately $605,470.36. This trade represents a 25.85% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last ninety days, insiders have sold 187,933 shares of company stock valued at $4,673,716. 33.51% of the stock is currently owned by insiders.

Institutional Trading of Zymeworks

A number of institutional investors have recently bought and sold shares of ZYME. Caitong International Asset Management Co. Ltd acquired a new stake in Zymeworks in the fourth quarter worth $37,000. Optiver Holding B.V. acquired a new stake in Zymeworks during the 3rd quarter worth approximately $26,000. Quarry LP bought a new position in Zymeworks in the third quarter valued at approximately $50,000. Mirae Asset Global Investments Co. Ltd. lifted its stake in Zymeworks by 25.2% in the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 3,637 shares of the company’s stock valued at $96,000 after buying an additional 731 shares in the last quarter. Finally, Tower Research Capital LLC TRC boosted its holdings in shares of Zymeworks by 29.6% in the second quarter. Tower Research Capital LLC TRC now owns 4,947 shares of the company’s stock valued at $62,000 after buying an additional 1,131 shares during the period. Institutional investors and hedge funds own 92.89% of the company’s stock.

Zymeworks News Summary

Here are the key news stories impacting Zymeworks this week:

• Positive Sentiment: Secured $250M non-recourse royalty‑backed note from Royalty Pharma — provides non-dilutive capital while only pledging 30% of Ziihera royalties, intended to preserve near‑term cash flows and fund share repurchases or strategic transactions. Royalty Financing
• Positive Sentiment: Ziihera regulatory/commercial progress — partner Jazz expects to complete the supplemental BLA for first‑line HER2+ GEA in 1Q26 with a potential H2 2026 launch; Zymeworks stands to receive up to $440M in GEA milestones plus tiered royalties, and recent approvals in Canada/UK further de‑risk near‑term royalty upside. Corporate Update
• Positive Sentiment: Analyst bullishness: Leerink Partners raised its price target to $58 and keeps an Outperform rating, signaling materially higher upside expectations vs. the current price and likely supporting buying interest. Leerink Price Target
• Positive Sentiment: Share buybacks underway — company has repurchased ~$62.5M of stock under its authorized program, reducing share count and supporting EPS if continued. Repurchase Update
• Neutral Sentiment: Full‑year results mixed: 2025 revenue rose ~39% to $106M and net loss narrowed year‑over‑year, with cash resources of ~$270.6M — improves runway but depends on milestone timing and partner commercialization. FY2025 Results
• Neutral Sentiment: Partner clinical updates: J&J presented pasritamig data at ASCO‑GU (supporting ongoing Phase 3 work); this is favorable but value accrual depends on future trial readouts and milestone captures. Pasritamig/Partner Data
• Negative Sentiment: Quarterly miss: Zymeworks reported Q4 EPS of ($0.55) vs. consensus ($0.35) and Q4 revenue was only $2.52M (down sharply YoY), which creates short‑term disappointment and explains some selling pressure. Earnings Miss
• Negative Sentiment: Insider and institutional selling: recent disclosures show notable insider sales and large institutional position reductions by some managers — could weigh on sentiment if sustained. Insider/Institutional Activity

About Zymeworks

Zymeworks Inc is a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of next-generation multifunctional biotherapeutics. The company specializes in engineered antibody and protein therapeutics designed to address a range of unmet medical needs in oncology and other serious diseases. Through its proprietary platforms, Zymeworks aims to create novel bispecific and multispecific molecules that can simultaneously engage multiple targets and recruit immune effector functions to enhance potency and specificity.

At the core of Zymeworks’ innovation is its Azymetric™ bispecific antibody platform, which enables the design of asymmetrical bispecific antibodies with controlled assembly and high stability.